Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium, in order to increase their rates of elimination.
From the U.S. FDA-approved label for Potassium ferric hexacyanoferrate (II).2H2O (Prussian blue). Full label: DailyMed.
Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium, in order to increase their rates of elimination.
From the U.S. FDA-approved label for Potassium ferric hexacyanoferrate (II).2H2O (Prussian blue). Full label: DailyMed.
Adults and Adolescents: 3 grams orally three times a day Pediatrics (2 – 12 years): 1 gram orally three times a day Administer as soon as possible after internal contamination with cesium or thallium is suspected 2.1 Important Administration Instructions Obtain quantitative baseline of the internalized contamination by radioactive cesium (137Cs) and/or thallium by appropriate whole-body counting and/or by bioassay (e.g., biodosimetry), or feces/urine samples, whenever possible prior to Radiogardase treatment. Initiate treatment with Radiogardase as soon as possible after contamination is suspected.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Increased radiation absorbed dose to gastrointestinal mucosa: Monitor for decreased gastrointestinal motility Constipation: Monitor and treat Electrolyte abnormalities: Monitor serum electrolytes during treatment Blue discoloration of stool, oral mucosa and dentition 5.1 Increased Radiation Absorbed Dose to Gastrointestinal Mucosa Radiogardase can decrease gastrointestinal motility, thus slowing the transit time of radioactivity in the gastrointestinal tract. The slowed transit time can increase the radiation absorbed dose to the gastrointestinal mucosa. 5.2 Constipation Radiogardase can cause constipation.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
Constipation was reported in 10 (24%) of 42 patients treated with Radiogardase. Severity of constipation was mild in 7 patients and moderate in 3 patients. Most common adverse reaction (incidence >24%) was constipation To report SUSPECTED ADVERSE REACTIONS, contact info@heyl-berlin.de, Fax +49 30 817 4049 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
Storage Store at 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C and 30°C (between 59 °F and 86 °F).
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
